

PHARMACEUTICAL MARKETING & PROMOTION

Opiant E
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmace
IPR2

These efforts have also been the subject of debate, with some questioning their value. This booklet offers facts about pharmaceutical marketing and promotion. We believe these facts are important to consider as the value of marketing and promotion are debated.

Since our last publication on marketing and promotion,¹ the pharmaceutical industry has worked to improve the dissemination of information about medical advances and to address concerns. One important change was the unanimous approval by PhRMA's Board of Directors of *Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines*. These voluntary Principles express the commitment of PhRMA members to deliver DTC communications that are a valuable contribution to public health.

In addition, in 2008 PhRMA adopted a newly revised *Code on Interactions with Health Care Professionals*. The strengthened code reflects a commitment to maintaining the highest ethical standards in all marketing practices and to promote the best patient care possible.

This publication shows the role of marketing and promotion in speeding the dissemination of valuable improvements in medical care. It also highlights the important role that marketing plays in getting patients to discuss a range of health issues with their physicians, resulting in patients receiving needed treatment.

We hope that the information contained in this booklet will enhance dialogue surrounding pharmaceutical marketing and promotion by providing a perspective that often is not heard. We look forward to further exploration of how best to get patients into needed treatment, and how to more rapidly and appropriately disseminate valuable medical technology.

¹Pharmaceutical Research and Manufacturers of America, "Tough Questions - Straight Answers Pharmaceutical Marketing & Promotion," (Washington, DC: PhRMA, Fall 2007), http://www.phrma.org/files/Tough_Questions.pdf.

other factors, including insurers' policies, affect prescribing decisions, often with greater impact. In fact, about 2 out of 3 medicines prescribed in the U.S. are generic—much higher than in nearly all other developed countries.

INFORMATION TO HEALTH CARE PROVIDERS 5

Government regulates the marketing of pharmaceuticals, and companies strive to provide reliable, valuable information. Delivering this information is key to making physicians aware of the latest advances.

SAMPLES 6

Samples provide many benefits to patients, allowing them to begin treatment sooner and helping them find the right medicine.

"GIFTS" TO HEALTH CARE PROVIDERS 7

PhRMA's member companies are committed to following the highest ethical standards and all legal requirements in their interactions with health care professionals. In 2008, they adopted a newly revised code that, among other things, redefines the narrow category of educational items company representatives can give to health care professionals.

DTC & PHYSICIAN / PATIENT RELATIONSHIP 8

Many physicians and patients report that DTC advertising enhances their communication.

UNDERDIAGNOSIS & UNDERTREATMENT 9

Studies report significant underdiagnosis and undertreatment of serious conditions that affect millions of Americans. While

patients to visit their doctor.

PATIENT EDUCATION & EMPOWERMENT 12

DTC advertising creates awareness of diseases and treatment options, helps get patients into needed treatment, and empowers patients with information.

DTC & PRESCRIBING PATTERNS 13

A majority of physicians report not feeling pressure to prescribe requested medications. In fact, many physicians recommend lifestyle changes and other treatments when patients request a specific medicine.

DTC ADVERTISING & DRUG PRICES / SPENDING 15

Government agencies and independent experts report no direct relationship between drug marketing and drug prices.

SPENDING ON PROMOTION AND R&D 17

Pharmaceutical companies are very research-intensive and spend significantly more on research and development than on marketing and promotion.

GOVERNMENT & INDUSTRY REGULATION 19

Pharmaceutical marketing is closely regulated by the U.S. Food and Drug Administration (FDA) to help assure that promotional materials are accurate, fairly balanced, and limited to information that has been approved by the FDA. Many pharmaceutical companies have also adopted voluntary pharmaceutical industry guidelines that lay out standards for interactions with health care providers and appropriate DTC marketing.

Opiant E
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmace
IPR2

& Prescribing Patterns

- A 2008 physician survey by KRC Research found that the vast majority of physicians say their clinical knowledge (**92%**) and a patient's unique situation (**88%**) greatly influence their prescribing decisions. **35%** point to patients' coverage and formulary as an important factor in prescribing, while just **11%** say that pharmaceutical company representatives greatly influence them. Surveys by Boston Consulting Group and Tufts Center for the Study of Drug Development echo these findings.
- **1/3** of physicians report that they do not always discuss treatment options that are not covered by an insurer.
- Approximately **67%** of all prescriptions used in the United States are generic. This is a sharp increase in recent years—**49%** of prescriptions in 2000 were for generics—and one of the highest generic use rates in the world.

(See pgs 3-4)

Information to Health Care Providers

- Nearly **90%** of physicians are either very satisfied (**29%**) or somewhat satisfied (**59%**) with the information they received from company representatives, according to the KRC survey. The BCG survey yielded similar results with over **90%** of physicians believing information from representatives to be either very valuable (**38%**) or somewhat valuable (**53%**).

(See pg 5)

Samples

- The 2008 KRC physician survey found **69%** of physicians believe free drug samples are

(**17%**). **95%** of physicians surveyed agreed that samples allow patients to start immediate treatment and **84%** said that samples provide them with useful first-hand experience.

- A recent Kaiser Family Foundation survey found that **75%** of physicians frequently (**58%**) or sometimes (**17%**) give patients samples to assist them with their out-of-pocket costs.

(See pg 6)

Physician / Patient Relationship

- According to an FDA survey, a vast majority (over **90%**) of patients who asked about a drug reported that their physician "welcomed the question."
- The FDA survey also polled **500** physicians and found that:
 - **73%** believed that DTC ads helped patients ask thoughtful questions.
 - **53%** of physicians considered the number one benefit of DTC ads to be the better discussions they had with their patients about their health.
 - **91%** of physicians said the patient did not try to influence the course of treatment in a way that would have been harmful.

(See pg 8)

Underdiagnosis & Undertreatment

- American patients receive about **1/2** of recommended care, according to a landmark 2003 study by RAND Health.
- The RAND Study also found that for quality standards related to medication, patients on average failed to receive recommended care **30%** of the time.

diagnosis.

- **46%** of physicians felt that DTC advertising increased patients' compliance with prescribed treatment.
- By treating patients according to guidelines and by eliminating the underuse of high blood pressure medicines, **89,000** lives could be saved and **420,000** hospitalizations avoided annually.

(See pgs 9-11)

Patient Education

- A 2007 KRC Research survey found that:
 - **1 in 4** consumers sought more information after seeing a DTC ad.
 - **4 in 5** consumers agree that advertising for prescription medicines can educate people about health conditions and treatment options.
- A *Prevention Magazine* physician survey found that **70%** of doctors feel that ads help educate patients about available treatments. **67%** felt that the advertisements helped them have better discussions with their patients.
- The FDA's 2004 survey showed that in **88%** of cases when patients ask their physicians about a medicine as a result of seeing a DTC advertisement, they have the condition that the drug treats.
- A *Prevention Magazine* patient survey found that **80%** of patients who see medicines advertised on television are aware of the risk information presented, compared to **66%** aware of the benefits.

(See pg 12)

insurer's formulary.

(See pgs 13-14)

DTC Advertising & Drug Prices / Spending

- According to the Federal Trade Commission, "[DTC advertising] can empower consumers to manage their own health care by providing information that will help them, with the assistance of their doctors, to make better informed decisions about their treatment options...Consumers receive these benefits from DTC advertising *with little, if any, evidence that such advertising increases prescription drug prices.*" [Emphasis Added]
- "The pharmaceutical industry is one of the most research-intensive industries in the United States. Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average U.S. manufacturing firm."
– Congressional Budget Office, 2006
- Total promotional spending 2006 – **\$12.0** billion
 - DTC – **\$4.8** billion
 - Office promotion, hospital promotion and journal advertising – **\$7.2** billion
- Total R&D spending 2007 – **\$58.8** billion

(See pgs 15-16)

Opiant E
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmace
IPR2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.